资讯
Molecular Partners在ASCO 2024上发布了MP0317（FAP X CD40 DARPin）单药物治疗晚期实体瘤完成的1期试验的积极数据。
Molecular Partners在ASCO 2024年年会上展示了MP0317的1期试验的最终数据，这是一种CD40激动剂。该研究纳入了46名患有晚期实体瘤的患者，并展示了良好的安全性和有前途的疗效。MP0317显示出在肿瘤微环境(TME)中定位，激活免疫细胞而不引起全身毒性。药物的安全性良好，常见副作用为轻度疲劳和输注反应。一名患者出现了尚未确认的部分反应，而有14名患者病情稳定。研究结果鼓励进一步进行临床试验，特别是结合疗法。
Molecular Partners在ASCO 2024年年会上展示了MP0317的1期试验的最终数据，这是一种CD40激动剂。该研究纳入了46名患有晚期实体瘤的患者，并展示了良好的安全性和有前途的疗效。MP0317显示出在肿瘤微环境(TME)中定位，激活免疫细胞而不引起全身毒性。药物的安全性良好，常见副作用为轻度疲劳和输注反应。一名患者出现了尚未确认的部分反应，而有14名患者病情稳定。研究结果鼓励进一步进行临床试验，特别是结合疗法。
2024年06月01日 - 上午05点00分
通过观察到的MP0317定位和肿瘤微环境中的免疫细胞激活来支持其作用机制
所有测试剂量水平均观察到了有利且可控的安全性概况
已建立了每周和每三周的给药方案，并得到了药代动力学和药效动力学的支持
数据支持在结合治疗中进一步临床评估MP0317
2024年6月1日，瑞士苏黎世州-ZURICH和美国马萨诸塞州康科德（Concord）—环球新闻社（GLOBE NEWSWIRE）--根据第53条LR的临时公告 Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company pioneering the design and development of a new class of custom-built protein drugs known as DARPin therapeutics, today announced it had presented the final data from its Phase 1 dose-escalation study of MP0317 at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, held in Chicago, IL, USA. MP0317 is a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment (TME) by anchoring to fibroblast activation protein (FAP) which is expressed in high amounts around tumors. This tumor-localized approach has the potential to deliver greater efficacy with fewer side effects compared to systemic CD40-targeting therapies.
通过观察到的MP0317定位和肿瘤微环境中的免疫细胞激活来支持其作用机制
所有测试剂量水平均观察到了有利且可控的安全性概况
已建立了每周和每三周的给药方案，并得到了药代动力学和药效动力学的支持
数据支持在结合治疗中进一步临床评估MP0317
2024年6月1日，瑞士苏黎世州-ZURICH和美国马萨诸塞州康科德（Concord）—环球新闻社（GLOBE NEWSWIRE）--根据第53条LR的临时公告 Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company pioneering the design and development of a new class of custom-built protein drugs known as DARPin therapeutics, today announced it had presented the final data from its Phase 1 dose-escalation study of MP0317 at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, held in Chicago, IL, USA. MP0317 is a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment (TME) by anchoring to fibroblast activation protein (FAP) which is expressed in high amounts around tumors. This tumor-localized approach has the potential to deliver greater efficacy with fewer side effects compared to systemic CD40-targeting therapies.
免责声明：社区由Moomoo Technologies Inc.提供，仅用于教育目的。
更多信息
评论
登录发表评论
